Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
AstraZeneca
Medtronic
Mallinckrodt
Johnson and Johnson

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR FLUORINE F-18


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Fluorine F-18

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00001849 ↗ New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 2 1999-05-20 Cushing Syndrome is an endocrine disorder causing an over production of the hormone cortisol. Cortisol is produced in the adrenal gland as a response to the production of corticotropin (ACTH) in the pituitary gland. Between 10% and 20% of patients with hypercortisolism (Cushing Syndrome) have ectopic production of the hormone ACTH. Meaning, the hormone is not being released from the normal site, the pituitary gland. In many cases the ectopic ACTH is being produced by a tumor of the lung, thymus, or pancreas. However, in approximately 50% of these patients the source of the ACTH cannot be found even with the use of extensive imaging studies such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and nuclear scans (111-indium pentetreotide). The ability of these tests to locate the source of the hormone production is dependent on the changes of anatomy and / or the dose and adequate uptake of the radioactive agent. The inability to detect the source of ectopic ACTH production often results in unnecessary pituitary surgery or irradiation. Unlike the previously described tests, positron emission tomography (PET scan) has the ability to detect pathologic tissue based on physiologic and biochemical processes within the abnormal tissue. This study will test whether fluorine-18-fluorodeoxyglucose (FDG), fluorine-18-dihydroxyphenylalanine (F-DOPA) or use of a higher dose of 111-indium pentetreotide can be used to successfully localize the source of ectopic ACTH production.
NCT00110006 ↗ Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma Withdrawn National Cancer Institute (NCI) N/A 2004-12-01 RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using fludeoxyglucose F 18, may help in learning how well chemotherapy works to kill cancer cells and allow doctors to plan better treatment. Comparing results of diagnostic procedures done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying positron emission tomography using fludeoxyglucose F 18 to see how well it works in predicting response to treatment in patients who are receiving rituximab and combination chemotherapy for newly diagnosed non-Hodgkin's lymphoma.
NCT00110006 ↗ Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma Withdrawn Case Comprehensive Cancer Center N/A 2004-12-01 RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using fludeoxyglucose F 18, may help in learning how well chemotherapy works to kill cancer cells and allow doctors to plan better treatment. Comparing results of diagnostic procedures done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying positron emission tomography using fludeoxyglucose F 18 to see how well it works in predicting response to treatment in patients who are receiving rituximab and combination chemotherapy for newly diagnosed non-Hodgkin's lymphoma.
NCT00110032 ↗ Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors Terminated National Cancer Institute (NCI) Phase 1 2005-06-01 This phase I trial is studying the side effects of fluorine F18 EF5 when given during positron emission tomography to find oxygen in tumor cells of patients who are undergoing surgery or biopsy for newly diagnosed brain tumors. Diagnostic procedures using fluorine F 18 EF5 and positron emission tomography to detect tumor hypoxia may help in planning cancer treatment
NCT00136968 ↗ Assessment of Voriconazole Penetration Into the Brain by Fluorine-Magnetic Resonance Spectroscopy Completed Mclean Hospital Phase 1 2005-04-01 The purpose of this study is to determine the amount of voriconazole in the brain by fluorine-magnetic resonance spectroscopy (MRS) and to compare brain levels to plasma levels.
NCT00136968 ↗ Assessment of Voriconazole Penetration Into the Brain by Fluorine-Magnetic Resonance Spectroscopy Completed Pfizer Phase 1 2005-04-01 The purpose of this study is to determine the amount of voriconazole in the brain by fluorine-magnetic resonance spectroscopy (MRS) and to compare brain levels to plasma levels.
NCT00204295 ↗ Study on Amino Acid Uptake in Brain Tumors Unknown status University Hospital Muenster Phase 2 2004-01-01 The purpose of this study is to determine the uptake of the amino acid O-(2-[F-18]Fluorethyl)-L-tyrosin (FET) in human brain tumors using positron emission tomography. A comparison to MRI and histopathological samples is used.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fluorine F-18

Condition Name

Condition Name for Fluorine F-18
Intervention Trials
Prostate Cancer 7
Adult Giant Cell Glioblastoma 4
Adult Glioblastoma 4
Adult Anaplastic Oligodendroglioma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fluorine F-18
Intervention Trials
Prostatic Neoplasms 11
Carcinoma 8
Glioma 7
Brain Neoplasms 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fluorine F-18

Trials by Country

Trials by Country for Fluorine F-18
Location Trials
United States 118
China 5
Germany 3
Korea, Republic of 3
Italy 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fluorine F-18
Location Trials
California 16
Michigan 7
Minnesota 7
New York 7
Missouri 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fluorine F-18

Clinical Trial Phase

Clinical Trial Phase for Fluorine F-18
Clinical Trial Phase Trials
Phase 4 4
Phase 3 2
Phase 2/Phase 3 3
[disabled in preview] 56
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fluorine F-18
Clinical Trial Phase Trials
Completed 34
Recruiting 18
Terminated 8
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fluorine F-18

Sponsor Name

Sponsor Name for Fluorine F-18
Sponsor Trials
National Cancer Institute (NCI) 23
Mayo Clinic 6
Washington University School of Medicine 3
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fluorine F-18
Sponsor Trials
Other 87
NIH 27
Industry 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Johnson and Johnson
Merck
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.